Clinical trial NCT03708263: Evaluation of the New Laser PHOTOLASE PLV-585nm for the Treatment of Rosacea
Official title: A Single-blinded, Monocentric, Randomized Pilot Study, to Evaluate the Yellow Laser PHOTOLASE PLV-585nm Versus the Reference Green Laser (KTP Excel V 532 nm) in the Treatment of Erythematotelangiectatic Rosacea
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Erythematotelangiectatic Rosacea
Keywords: 532 nm green Laser
585 nm yellow laser
rosacea
telangiectasis score
skin disease
Lead sponsor: University Hospital, Lille
Sponsor class: OTHER
Collaborators: name: Institut National de la Santé Et de la Recherche Médicale, France
name: Medical Research Fund of the Tampere University Hospital, Finland
First posted: 2018-10-17
Enrollment: 1
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Rosacea is a frequent dermatological condition, with a chronic and disturbing evolution that is characterized by redness, permanent erythema associated with telangiectasia (visible and permanent dilatation of the small vessels). It frequently affects men and women with fair skin and can have significant psycho-emotional consequences.

To counteract the unaesthetic appearance of redness and eliminate telangiectasia, the use of the laser is proposed to the patient.

This study is a single center prospective, randomized, controlled split face study to compare 532nm KTP laser versus 585 nm PLV Laser in terms of improvement of the symptoms in the treatment of Erythematotelangiectatic Rosacea 20 subjects will receive up to 3 laser treatments at day 0, month 2 and 4 and will be followed at month 6 and 12.

Detailed description: Adult male and female subjects 18 years of age or older will participate in the study after the objectives, methods, and potential risks of the study have been explained, and after they have signed the informed consent form.

Patients will come to the investigation center for a maximum of 6 visits.

Eligibility criteria: Inclusion Criteria:

* Fitzpatrick Skin Type I - III
* Post-menopausal or surgically sterilized, or using a medically acceptable form of birth control at least 3 months prior to enrolment and during the entire course of the study.
* Clinical diagnosis of Erythematotelangiectatic Rosacea stade II
* Homogeneous extend and staining telangiectasia in each half face
* Patient never treated with laser for Rosacea
* Patient doesn't wish to use systemic corticosteroids or retinoids; or topical corticosteroids or retinoids on the treated area.
* Patient agreeing to have limited exposure to the sun and use of a protective screen (index 50 or higher) every day of the study and throughout its duration if it takes place from May to September.
* Patient must be able to read, understand and sign the Informed Consent Form
* Patient able to adhere to the program of visits of the study and the other imperatives of the protocol
* Patient accepting to have photographs taken on the face
* Quality of social insurance or social security entitlement

Exclusion Criteria:

* Pregnant and/or breastfeeding woman or childbearing age without effective contraception
* Alcohol abuse assessed at the discretion of the investigator
* History of prior laser or light based procedures for any other pathology for the face within 6 months of study participation Fitzpatrick Type IV à VI
* Systemic use of isotretinoin in the 6 months prior to inclusion in the study.
* Topical use of retinoids and / or corticosteroids in the 4 weeks prior to inclusion in the study.
* Patient under photo sensitization treatment
* Patient suffering from significant concurrent illness such as type 1 diabetes, cardiovascular disease, uncontrolled hypertension, neurological disease, lupus erythematosus, scleroderma.
* Patient subject to hypertrophic or abnormal scarring
* Patient presenting or having a malignant tumor or skin cancer in the area to be treated.
* Having a known anticoagulative condition or taking prescription anticoagulation medications.
* Participation to another clinical study involving a laser or drug within three months of inclusion in the study.
* Smoker or former smoker in the 12 months prior to inclusion in the study.
* Patient with excessive tattoos in the area to be treated and / or wishing to tattoo the treated area during the study.
* Patient treated for cancer by chemotherapy or radiotherapy
* Patient with hyper or hypo pigmentation
* Patient unable to understand protocol or give consent
* Legal incapacity (persons deprived of their liberty or under guardianship or curatorship)
* Patient in emergency or in detention
* Clinical follow-up impossible for psychological, family matters, social or geographical reasons

Primary outcomes:
measure: Degree of improvement in Erythematotelangiectatic Rosacea
timeFrame: at Month 2
Secondary outcomes:
measure: Degree of improvement in Erythematotelangiectatic Rosacea evaluated by a blinded physician.
timeFrame: at Month 4, 6,12
measure: Measures of skin reaction for each treatment arm
timeFrame: At baseline, At Month 2, At Month 4 (if realized)
measure: Pain evaluation during each treatment
timeFrame: At baseline, At Month 2, At Month 4 (if realized)
measure: Change in lesion skin color in each treatment arm
timeFrame: At Baseline, at Month 2, 4, 6,12
measure: Subject satisfaction level
timeFrame: At Month 6,12
measure: Change in Life Quality
timeFrame: At Selection, at Baseline, at Month 2, 4 (if realized), 6,12
measure: Practitioner's opinion
timeFrame: At baseline, At Month 2, At Month 4 (if realized)
measure: Adverse Events
timeFrame: At Baseline, At Month 2, 4, 6,12
Other outcomes:
Locations:
city: Lille
country: France
facility: Hop Claude Huriez Chu Lille
Study officials:
affiliation: University Hospital, Lille
name: Cyril MAIRE, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Institut National de la Santé Et de la Recherche Médicale, France
name: Serge MORDON, Pr
role: STUDY_DIRECTOR
References: